Quesada S, Solassol J, Ray-Coquard I, Fabbro M [Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey]. Bull Cancer. 2023;110(4):371-381. doi:10.1016/j.bulcan.2023.02.004
Mailliez A, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero J-M, Petit T, Mouret-Reynier M, Eymard J-C, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Simon G, Jacot W, Delaloge S Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2023;152(5):921-931. doi:10.1002/ijc.34304
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton N, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard M, Conde E, Copin M, Côté J, D'Haene N, Dai H, de Leval L, Delongova P, Den?i?-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin J, Mertz K, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti M, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin J, Salmon I, Prince S, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Je?ek S, Solassol J, Steinestel K, Stoj?i? J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl S, Stenzinger A, Ilié M Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open. 2023;8(5):101628. doi:10.1016/j.esmoop.2023.101628
Aptecar L, Puech C, Lopez-Crapez E, Peter M, Coopman P, D'Hondt V, Freiss G PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells. Int J Mol Sci. 2023;24(20):15413. doi:10.3390/ijms242015413
Fabbro M, Jacot W, Jarlier M, Guiu S, D'Hondt V, Champoiral P, Janiszewski C, Nicklès I Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study. Cancer Rep (Hoboken). 2023;6(1):e1732. doi:10.1002/cnr2.1732
Safieddine A, Coleno E, Lionneton F, Traboulsi A-M, Salloum S, Lecellier C-H, Gostan T, Georget V, Hassen-Khodja C, Imbert A, Mueller F, Walter T, Peter M, Bertrand E HT-smFISH: a cost-effective and flexible workflow for high-throughput single-molecule RNA imaging. Nat Protoc. 2023;18(1):157-187. doi:10.1038/s41596-022-00750-2
Vendrell J, Ban I, Solassol I, Audran P, Cabello-Aguilar S, Topart D, Lindet-Bourgeois C, Colombo P-E, Legouffe E, D'Hondt V, Fabbro M, Solassol J Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. Int J Mol Sci. 2023;24(18):14181. doi:10.3390/ijms241814181
Kurtz J-E, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier M-A, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz J-P, Largillier R, Heudel P-E, Heitz F Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023;41(30):4768-4778. doi:10.1200/JCO.23.00529
Dahmani C, Corre E, Dandou S, Mangé A, Radulescu O, Coopman P, Cuq P, Larive R [Resistance to BRAF inhibitors: A lesson from clinical observations]. Med Sci (Paris). 2022;38(6-7):570-578. doi:10.1051/medsci/2022083
Thomas Q, Quesada S, D'Hondt V, Belaroussi I, Laas E, Classe J-M, Fabbro M, Colombo P-E [Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?]. Bull Cancer. 2022;109(2):197-215. doi:10.1016/j.bulcan.2021.11.013
Falandry C, Pommeret F, Gladieff L, Tinquaut F, Lorusso D, Mouret-Reynier M-A, D'Hondt V, Mollon-Grange D, Floquet A, Abadie-Lacourtoisie S, Brachet P-E, Stefani L, Rousseau F, Frenel J-S, Del Piano F, Komulainen M, Warkus T, Pujade-Lauraine E, Freyer G Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. Lancet Healthy Longev. 2022;3(3):e176-e185. doi:10.1016/S2666-7568(22)00002-2
Quesada S, Fabbro M, Solassol J Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. Cancers (Basel). 2022;14(5):1132. doi:10.3390/cancers14051132
Quesada S, Fabbro M, Solassol J Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers (Basel). 2022;14(4):1098. doi:10.3390/cancers14041098
Bidard F-C, Hardy-Bessard A-C, Dalenc F, Bachelot T, Pierga J-Y, Sabatier R, Dubot C, Frenel J-S, Ferrero J, Ladoire S, Levy C, Mouret-Reynier M-A, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza J, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon J-L, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Delaloge S Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367-1377. doi:10.1016/S1470-2045(22)00555-1
Delaloge S, Dureau S, D'Hondt V, Desmoulins I, Heudel P-E, Duhoux F, Levy C, Lerebours F, Mouret-Reynier M, Dalenc F, Frenel J-S, Jouannaud C, Venat-Bouvet L, Nguyen S, Callens C, Gentien D, Rapinat A, Manduzio H, Vincent-Salomon A, Lemonnier J, Cottu P Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer. 2022;166. doi:10.1016/j.ejca.2022.01.014
Bobrie A, Jarlier M, Moussion A, Jacot W Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures. Support Care Cancer. 2022;30(4):3633-3641. doi:10.1007/s00520-022-06810-3
Marce M, Delaloge S, Hardy-Bessard A-C, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon J-L, André F, Arnould L, Clatot F, Lemonnier J, Marques S Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 2022;12(3):e055821. doi:10.1136/bmjopen-2021-055821
Coopman P Protein Phosphorylation in Cancer: Unraveling the Signaling Pathways. Biomolecules. 2022;12(8):1036. doi:10.3390/biom12081036
Soudier P, Zúñiga A, Duigou T, Voyvodic P, Bazi-Kabbaj K, Kushwaha M, Vendrell J, Bonnet J, Faulon J-L PeroxiHUB: A Modular Cell-Free Biosensing Platform Using H2O2 as Signal Integrator. ACS Synth Biol. 2022;11(8):2578-2588. doi:10.1021/acssynbio.2c00138
Cabello-Aguilar S, Vendrell J, Van Goethem C, Brousse M, Gozé C, Frantz L, Solassol J ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets. Mol Ther Nucleic Acids. 2022;30. doi:10.1016/j.omtn.2022.09.009
Vendrell J, Henry S, Cabello-Aguilar S, Heckendorn E, Godreuil S, Solassol J Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota. Int J Mol Sci. 2022;23(3):1336. doi:10.3390/ijms23031336
de Calbiac O, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier M-A, Emile G, Jouannaud C, Patsouris A, Leheurteur M, Petit T, Cottu P, Ferrero J-M, D'Hondt V, Desmoulins I, Mourato-Ribeiro J, Martin A-L, Frenel J-S Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France. JAMA Netw Open. 2022;5(9):e2231170. doi:10.1001/jamanetworkopen.2022.31170
Thomas Q, Colard-Thomas J, Delansay D, Leenhardt F, Vendrell J, Quantin X Case report: Liquid biopsy, the sooner the better?. Front Oncol. 2022;12. doi:10.3389/fonc.2022.1089108
Pichon X, Moissoglu K, Coleno E, Wang T, Imbert A, Robert M-C, Peter M, Chouaib R, Walter T, Mueller F, Zibara K, Bertrand E, Mili S The kinesin KIF1C transports APC-dependent mRNAs to cell protrusions. RNA. 2021;27(12):1528-1544. doi:10.1261/rna.078576.120
Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy M-P, D'Hondt V, Dalenc F, Ferrero J-M, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard J-C, Breton M, Chevrot M, Thureau S, Petit T, Simon G Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol. 2021;13. doi:10.1177/1758835920987657
Institut de Recherche en Cancérologie de
